Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YZacks Investment Research • 05/01/26
PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline UpdateGlobeNewsWire • 04/30/26
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to ShareholdersGlobeNewsWire • 04/28/26
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?Zacks Investment Research • 04/27/26
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip ArthroplastyGlobeNewsWire • 04/27/26
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026GlobeNewsWire • 04/16/26
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresGlobeNewsWire • 04/13/26
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/08/26
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual MeetingGlobeNewsWire • 03/30/26
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.PRNewsWire • 03/12/26
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare ConferenceGlobeNewsWire • 03/04/26
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock DownZacks Investment Research • 02/27/26
Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/27/26
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewsWire • 02/26/26